LT5004B - Torsemido polimorfai - Google Patents
Torsemido polimorfai Download PDFInfo
- Publication number
- LT5004B LT5004B LT2002017A LT2002017A LT5004B LT 5004 B LT5004 B LT 5004B LT 2002017 A LT2002017 A LT 2002017A LT 2002017 A LT2002017 A LT 2002017A LT 5004 B LT5004 B LT 5004B
- Authority
- LT
- Lithuania
- Prior art keywords
- torsemide
- modification
- solvent
- adduct
- mixture
- Prior art date
Links
- NGBFQHCMQULJNZ-UHFFFAOYSA-N Torsemide Chemical compound CC(C)NC(=O)NS(=O)(=O)C1=CN=CC=C1NC1=CC=CC(C)=C1 NGBFQHCMQULJNZ-UHFFFAOYSA-N 0.000 title claims abstract description 449
- 229960005461 torasemide Drugs 0.000 title claims abstract description 434
- 230000004048 modification Effects 0.000 claims abstract description 178
- 238000012986 modification Methods 0.000 claims abstract description 178
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 94
- 238000000034 method Methods 0.000 claims abstract description 65
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims abstract description 57
- 239000002904 solvent Substances 0.000 claims abstract description 51
- 238000002360 preparation method Methods 0.000 claims abstract description 22
- 230000008569 process Effects 0.000 claims abstract description 19
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 9
- 239000000203 mixture Substances 0.000 claims description 61
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 54
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 41
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 36
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 33
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical group [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 24
- 239000000725 suspension Substances 0.000 claims description 20
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 claims description 18
- 238000006243 chemical reaction Methods 0.000 claims description 18
- 238000001914 filtration Methods 0.000 claims description 16
- 239000002253 acid Substances 0.000 claims description 15
- 238000001035 drying Methods 0.000 claims description 15
- 238000004519 manufacturing process Methods 0.000 claims description 14
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 claims description 12
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims description 12
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 claims description 11
- 239000000908 ammonium hydroxide Substances 0.000 claims description 11
- 238000000634 powder X-ray diffraction Methods 0.000 claims description 11
- 239000011877 solvent mixture Substances 0.000 claims description 11
- 206010030113 Oedema Diseases 0.000 claims description 10
- 238000002441 X-ray diffraction Methods 0.000 claims description 10
- 239000000843 powder Substances 0.000 claims description 9
- 239000003960 organic solvent Substances 0.000 claims description 8
- 238000010438 heat treatment Methods 0.000 claims description 6
- 238000002156 mixing Methods 0.000 claims description 6
- 230000015572 biosynthetic process Effects 0.000 claims description 5
- 150000001875 compounds Chemical class 0.000 claims description 5
- 238000004108 freeze drying Methods 0.000 claims description 5
- 238000002329 infrared spectrum Methods 0.000 claims description 5
- 229910021529 ammonia Inorganic materials 0.000 claims description 4
- 238000001816 cooling Methods 0.000 claims description 3
- 239000003814 drug Substances 0.000 claims description 3
- 239000011261 inert gas Substances 0.000 claims description 3
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 claims description 3
- 238000009835 boiling Methods 0.000 claims description 2
- 230000001376 precipitating effect Effects 0.000 claims description 2
- 238000002955 isolation Methods 0.000 claims 2
- 125000003158 alcohol group Chemical group 0.000 claims 1
- 238000003756 stirring Methods 0.000 description 15
- 235000011114 ammonium hydroxide Nutrition 0.000 description 9
- 238000004566 IR spectroscopy Methods 0.000 description 7
- 239000003937 drug carrier Substances 0.000 description 7
- 239000002244 precipitate Substances 0.000 description 7
- 239000011541 reaction mixture Substances 0.000 description 7
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 6
- 239000000706 filtrate Substances 0.000 description 6
- 239000007787 solid Substances 0.000 description 6
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 5
- 238000002411 thermogravimetry Methods 0.000 description 5
- 238000001757 thermogravimetry curve Methods 0.000 description 5
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical class Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical class OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 4
- 150000007513 acids Chemical class 0.000 description 4
- 239000013078 crystal Substances 0.000 description 4
- 238000000113 differential scanning calorimetry Methods 0.000 description 4
- 238000010992 reflux Methods 0.000 description 4
- 238000000862 absorption spectrum Methods 0.000 description 3
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
- 206010007559 Cardiac failure congestive Diseases 0.000 description 2
- 206010019280 Heart failures Diseases 0.000 description 2
- 206010020772 Hypertension Diseases 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- 208000017169 kidney disease Diseases 0.000 description 2
- 208000019423 liver disease Diseases 0.000 description 2
- VTHJTEIRLNZDEV-UHFFFAOYSA-L magnesium dihydroxide Chemical compound [OH-].[OH-].[Mg+2] VTHJTEIRLNZDEV-UHFFFAOYSA-L 0.000 description 2
- 239000000347 magnesium hydroxide Substances 0.000 description 2
- 229910001862 magnesium hydroxide Inorganic materials 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- 239000011707 mineral Chemical class 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonium chloride Substances [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 1
- 238000005033 Fourier transform infrared spectroscopy Methods 0.000 description 1
- 239000001828 Gelatine Substances 0.000 description 1
- 235000010582 Pisum sativum Nutrition 0.000 description 1
- 240000004713 Pisum sativum Species 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052786 argon Inorganic materials 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 208000020832 chronic kidney disease Diseases 0.000 description 1
- 208000022831 chronic renal failure syndrome Diseases 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 229940066468 demadex Drugs 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000004807 desolvation Methods 0.000 description 1
- 229910001873 dinitrogen Inorganic materials 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 230000001882 diuretic effect Effects 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 230000003595 spectral effect Effects 0.000 description 1
- 239000006190 sub-lingual tablet Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pyridine Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Details Of Garments (AREA)
- Measuring Pulse, Heart Rate, Blood Pressure Or Blood Flow (AREA)
- Pressure Welding/Diffusion-Bonding (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US14830599P | 1999-08-11 | 1999-08-11 | |
| US18312700P | 2000-02-17 | 2000-02-17 | |
| US21527300P | 2000-06-30 | 2000-06-30 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| LT2002017A LT2002017A (en) | 2002-11-25 |
| LT5004B true LT5004B (lt) | 2003-03-25 |
Family
ID=27386674
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| LT2002017A LT5004B (lt) | 1999-08-11 | 2002-02-11 | Torsemido polimorfai |
Country Status (24)
| Country | Link |
|---|---|
| US (1) | US6465496B1 (enExample) |
| EP (1) | EP1207880A4 (enExample) |
| JP (1) | JP2003527319A (enExample) |
| KR (1) | KR20020025217A (enExample) |
| CN (1) | CN1378448A (enExample) |
| AU (1) | AU781461C (enExample) |
| BG (1) | BG106400A (enExample) |
| CA (1) | CA2379322A1 (enExample) |
| CZ (1) | CZ2002404A3 (enExample) |
| DE (1) | DE00957398T1 (enExample) |
| ES (1) | ES2204354T1 (enExample) |
| HK (1) | HK1046636A1 (enExample) |
| HR (1) | HRP20020120A2 (enExample) |
| HU (1) | HUP0204318A3 (enExample) |
| IL (1) | IL148031A0 (enExample) |
| LT (1) | LT5004B (enExample) |
| MX (1) | MXPA02001369A (enExample) |
| NO (1) | NO20020622L (enExample) |
| PL (1) | PL354262A1 (enExample) |
| SI (1) | SI20816A (enExample) |
| SK (1) | SK1912002A3 (enExample) |
| TR (1) | TR200200353T2 (enExample) |
| WO (1) | WO2001010441A1 (enExample) |
| YU (1) | YU9502A (enExample) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SK11632003A3 (sk) * | 2000-02-17 | 2004-04-06 | Teva Pharmaceutical Industries Ltd. | Stabilný farmaceutický prípravok obsahujúci modifikáciu II torsemidu |
| DE10013289A1 (de) * | 2000-03-17 | 2001-09-20 | Knoll Ag | Torasemid enthaltende pharmazeutische Zubereitungen |
| HRP20000162B1 (en) | 2000-03-20 | 2004-06-30 | Pliva D D | Amorphous torasemide modification |
| US20030022921A1 (en) * | 2001-02-21 | 2003-01-30 | Minutza Leibovici | Stable pharmaceutical formulation comprising torsemide modification II |
| EP1397343A1 (en) | 2001-05-31 | 2004-03-17 | Orion Corporation Fermion | Process for preparing sertraline hydrochloride polymorphic form ii |
| IN192178B (enExample) | 2001-08-03 | 2004-03-06 | Ranbaxy Lab | |
| US20030119882A1 (en) * | 2001-10-22 | 2003-06-26 | Markus Maegerlein | Solid pharmaceutical composition containing torasemide |
| ITMI20020639A1 (it) * | 2002-03-27 | 2003-09-29 | Cosma S P A | Composizioni farmaceutiche comprendenti come principio attivo 1-isopropil-3°(4-m-toluidino-3-pridil)sulfonil!-urea |
| HRP20020603B1 (en) * | 2002-07-19 | 2008-11-30 | Pliva D.D. | New process for the preparation of modification i n-(1-methylethylaminocarbonyl)-4-(3-methylphenylamino)-3-pyridinesulfonamide |
| CA2424644A1 (en) * | 2003-04-07 | 2004-10-07 | David John Mckenzie | Preparation of torasemide |
| ES2244324B1 (es) * | 2004-03-25 | 2006-11-16 | Ferrer Internacional, S.A. | Composiciones diureticas de liberacion prolongada. |
| AT500576B1 (de) * | 2004-07-28 | 2006-11-15 | Sanochemia Pharmazeutika Ag | Verfahren zur reindarstellung von kristallformen von torsemid |
| KR100845383B1 (ko) * | 2004-12-24 | 2008-07-09 | 일동제약주식회사 | 토르세미드 변형체(ⅰ)의 제조방법 |
| US20070122483A1 (en) * | 2005-11-29 | 2007-05-31 | Sharon Myers | Fluocinolone acetonide drug substance polymorphic interconversion |
| AU2014348523B2 (en) | 2013-11-15 | 2019-01-03 | Akebia Therapeutics, Inc. | Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid, compositions, and uses thereof |
| CN105949115A (zh) * | 2016-05-26 | 2016-09-21 | 南京正科医药股份有限公司 | 一种新晶型托拉塞米 |
| CN115417810B (zh) * | 2022-09-22 | 2023-10-10 | 南京正科医药股份有限公司 | 一种托拉塞米晶型ⅰ的精制方法 |
| CN117486789A (zh) * | 2023-12-29 | 2024-02-02 | 江西中医药大学 | 一种托拉塞米共晶盐及其制备方法和应用 |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US30633A (en) | 1860-11-13 | Improvement in fire-escapes | ||
| US34672A (en) | 1862-03-18 | Improved convertible boat, bridge, and tent | ||
| US4822807A (en) | 1985-08-17 | 1989-04-18 | Boehringer Mannheim Gmbh | Pharmaceutical composition containing a stable modification of torasemide |
| US5914336A (en) | 1998-06-02 | 1999-06-22 | Boehringer Mannheim Gmbh | Method of controlling the serum solubility of orally administered torasemide and composition relating thereto |
| WO2000020395A1 (en) | 1998-10-02 | 2000-04-13 | Pliva, Farmaceutska Industrija, Dionicko Drustvo | New crystal modification iii of torasemide |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1477664A (en) | 1974-04-17 | 1977-06-22 | Christiaens Sa A | Pyridine derivatives |
| US4055650A (en) | 1974-04-17 | 1977-10-25 | A. Christiaens Societe Anonyme | Certain 4-phenoxy(or phenylthio)-3-n-acylated-sulfonamido-pyridines |
| DE3623620A1 (de) | 1986-07-12 | 1988-01-21 | Boehringer Mannheim Gmbh | Spritzfertige, waessrige, alkalische injektionsloesungen von torasemid und verfahren zu ihrer herstellung |
| US6166045A (en) * | 1998-06-02 | 2000-12-26 | Roche Diagnostics Gmbh | Torasemide of modification III |
| HRP20000162B1 (en) * | 2000-03-20 | 2004-06-30 | Pliva D D | Amorphous torasemide modification |
| CA2403382A1 (en) * | 2000-03-20 | 2001-09-27 | Teva Pharmaceutical Industries Ltd. | Novel processes for preparing torsemide intermediate |
| HRP20000328A2 (en) * | 2000-05-19 | 2002-02-28 | Pliva Farmaceutska Ind Dionik | Novel polymorph v of torasemide |
-
2000
- 2000-08-11 HR HR20020120A patent/HRP20020120A2/hr not_active Application Discontinuation
- 2000-08-11 WO PCT/US2000/022081 patent/WO2001010441A1/en not_active Ceased
- 2000-08-11 EP EP00957398A patent/EP1207880A4/en not_active Withdrawn
- 2000-08-11 DE DE0001207880T patent/DE00957398T1/de active Pending
- 2000-08-11 PL PL00354262A patent/PL354262A1/xx not_active Application Discontinuation
- 2000-08-11 HK HK02108111.5A patent/HK1046636A1/zh unknown
- 2000-08-11 AU AU69026/00A patent/AU781461C/en not_active Ceased
- 2000-08-11 TR TR2002/00353T patent/TR200200353T2/xx unknown
- 2000-08-11 KR KR1020027001867A patent/KR20020025217A/ko not_active Ceased
- 2000-08-11 MX MXPA02001369A patent/MXPA02001369A/es unknown
- 2000-08-11 US US09/638,106 patent/US6465496B1/en not_active Expired - Fee Related
- 2000-08-11 SK SK191-2002A patent/SK1912002A3/sk unknown
- 2000-08-11 CN CN00814045A patent/CN1378448A/zh active Pending
- 2000-08-11 CA CA002379322A patent/CA2379322A1/en not_active Abandoned
- 2000-08-11 SI SI200020037A patent/SI20816A/sl not_active IP Right Cessation
- 2000-08-11 CZ CZ2002404A patent/CZ2002404A3/cs unknown
- 2000-08-11 JP JP2001514958A patent/JP2003527319A/ja not_active Withdrawn
- 2000-08-11 ES ES00957398T patent/ES2204354T1/es active Pending
- 2000-08-11 IL IL14803100A patent/IL148031A0/xx unknown
- 2000-08-11 HU HU0204318A patent/HUP0204318A3/hu unknown
- 2000-08-11 YU YU9502A patent/YU9502A/sh unknown
-
2002
- 2002-02-08 NO NO20020622A patent/NO20020622L/no not_active Application Discontinuation
- 2002-02-08 BG BG106400A patent/BG106400A/xx unknown
- 2002-02-11 LT LT2002017A patent/LT5004B/lt unknown
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US30633A (en) | 1860-11-13 | Improvement in fire-escapes | ||
| US34672A (en) | 1862-03-18 | Improved convertible boat, bridge, and tent | ||
| US4822807A (en) | 1985-08-17 | 1989-04-18 | Boehringer Mannheim Gmbh | Pharmaceutical composition containing a stable modification of torasemide |
| US5914336A (en) | 1998-06-02 | 1999-06-22 | Boehringer Mannheim Gmbh | Method of controlling the serum solubility of orally administered torasemide and composition relating thereto |
| WO2000020395A1 (en) | 1998-10-02 | 2000-04-13 | Pliva, Farmaceutska Industrija, Dionicko Drustvo | New crystal modification iii of torasemide |
Non-Patent Citations (1)
| Title |
|---|
| L. DUPONT, ET AL.: "Structure d une seconde variete de la torasemide", ACTA CRYSTALLOGRAPHICA SECTION B, 1978, pages 2659 - 2662, XP002128456, DOI: doi:10.1107/S0567740878008900 |
Also Published As
| Publication number | Publication date |
|---|---|
| ES2204354T1 (es) | 2004-05-01 |
| US6465496B1 (en) | 2002-10-15 |
| HUP0204318A3 (en) | 2005-03-29 |
| CA2379322A1 (en) | 2001-02-15 |
| JP2003527319A (ja) | 2003-09-16 |
| NO20020622L (no) | 2002-03-14 |
| IL148031A0 (en) | 2002-09-12 |
| MXPA02001369A (es) | 2005-08-26 |
| HK1046636A1 (zh) | 2003-01-24 |
| PL354262A1 (en) | 2003-12-29 |
| NO20020622D0 (no) | 2002-02-08 |
| CZ2002404A3 (cs) | 2002-06-12 |
| EP1207880A1 (en) | 2002-05-29 |
| AU781461B2 (en) | 2005-05-26 |
| AU781461C (en) | 2006-02-23 |
| CN1378448A (zh) | 2002-11-06 |
| SK1912002A3 (en) | 2002-07-02 |
| EP1207880A4 (en) | 2004-09-01 |
| WO2001010441A1 (en) | 2001-02-15 |
| LT2002017A (en) | 2002-11-25 |
| HUP0204318A2 (en) | 2003-05-28 |
| DE00957398T1 (de) | 2004-04-15 |
| TR200200353T2 (tr) | 2002-06-21 |
| HRP20020120A2 (en) | 2003-10-31 |
| SI20816A (sl) | 2002-08-31 |
| BG106400A (en) | 2002-08-30 |
| KR20020025217A (ko) | 2002-04-03 |
| YU9502A (sh) | 2005-06-10 |
| AU6902600A (en) | 2001-03-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| LT5004B (lt) | Torsemido polimorfai | |
| US7598396B2 (en) | Crystalline solids of carvedilol and processes for their preparation | |
| AU2002366383B2 (en) | Polymorphs of clopidogrel hydrogensulfate | |
| ZA200407799B (en) | Lansoprazole polymorphs and processes for preparation thereof | |
| JP2007514000A (ja) | テガセロッド塩基及びその塩の多形現象形 | |
| WO2008149155A1 (en) | Crystalline form b of olmesartan medoxomil | |
| RU2220137C2 (ru) | Термодинамически устойчивая форма (r)-3-[[(4-фторфенил)-сульфонил]амино]-1,2,3,4-тетрагидро-9н-карбазол-9-пр опановой кислоты (раматробана) | |
| US20070260068A1 (en) | Method for the Preparation of Crystal Forms of Torsemide in a Pure State | |
| EP4433461A1 (en) | Solid state form of tafamidis | |
| KR20080086937A (ko) | 나테글리나이드의 다형태 | |
| EP4178679A1 (en) | Solid state forms of n-[2-(2-{4-[2-(6,7-dimethoxy-3,4-dihydro-2(1h)-isoquinolinyl)ethyl]phenyl}-2h-tetrazol-5-yl)-4,5-dimethoxyphenyl]-4-oxo-4h-chromene-2-carboxamide mesylate salt | |
| WO2021119223A1 (en) | Solid state form of lemborexant | |
| ZA200200967B (en) | Tomsemide Polymorphs. | |
| EP1713769B1 (en) | Amorphous tamsulosin hydrochloride | |
| WO2004076406A2 (en) | Losartan potassium polymorphs and process for the preparation thereof | |
| AU2007200344A1 (en) | Carvedilol |